Welcome to Awesome Blog Design perfect blog
Business, Healthcare, Local News

U.S. Food and Drug Administration approves OPDIVO® (nivolumab) in combination with CABOMETYX® (cabozantinib) as first-line treatment for patients with advanced renal cell carcinoma

In CheckMate -9ER, OPDIVO in combination with CABOMETYX doubled median progression-free survival and objective response rate and showed superior overall survival vs. sunitinib1 Approved across all International Metastatic Renal Cell Carcinoma Database Consortium risk categories1,2 Approval expands Company’s presence in first-line advanced